Peter Hecht, Cyclerion Therapeutics CEO
October 6, 2022 10:35 AM EDT
People
R&D

Iron­wood's for­mer pipeline spin­out hits an­oth­er speed bump, lay­ing off 45% and turn­ing to­ward the mi­to­chon­dria

Max Gelman

Senior Editor

To the cha­grin of the sec­tor, an­oth­er biotech is con­duct­ing lay­offs Thurs­day while mak­ing a some­what sig­nif­i­cant turn — its sec­ond in the last 24 months …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J takes 340B fight with fed­er­al gov­ern­ment to court

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times